What is Vaxcyte?
Vaxcyte is dedicated to enhancing global health through the creation of superior and innovative vaccines. Headquartered in San Carlos, California, the company focuses on developing preventative and therapeutic vaccines for some of the world's most common and dangerous infectious diseases. Its strategic approach involves leveraging cutting-edge science to address unmet medical needs, positioning it as a key player in the biopharmaceutical sector. The company's commitment to improving public health through advanced vaccine technology is a cornerstone of its mission.
How much funding has Vaxcyte raised?
Vaxcyte has raised a total of $1.1B across 7 funding rounds:
Series A
$22M
Series B
$60M
Other Financing Round
$4M
Series C
$85M
Series D
$110M
Stock Offering
$100M
Share Placement
$750M
Series A (2015): $22M with participation from Longitude Capital, Roche, CTI Life Sciences Fund, and Abingworth
Series B (2017): $60M led by Longitude Capital, Roche, Abingworth, Frazier Healthcare Partners, CTI Life Sciences Fund, and Pivotal Bioventure Partners
Other Financing Round (2017): $4M supported by Longitude Capital, Roche, Abingworth, and CTI Life Sciences Fund
Series C (2018): $85M, investors not publicly disclosed
Series D (2020): $110M backed by Foresite Capital, Frazier Health Care Partners, Abingworth LLP, Pivotal Bioventure Partners, CTI Life Sciences, Medixc, Texas Pacific Group, Janus Henderson Group, Longitude Capital, Roche, and RA Capital Management , LLC
Stock Issuance/Offering (2022): $100M, investors not publicly disclosed
Share Placement (2024): $750M, investors not publicly disclosed
Key Investors in Vaxcyte
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
Abingworth LLP
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies.
Longitude Capital
Longitude Capital is a healthcare focused venture capital firm that invests in biotechnology, medical technology and health solutions companies, pairing sector expertise, flexible capital and active partnership to help innovators scale and improve patient care.
What's next for Vaxcyte?
With a history of significant capital infusions, Vaxcyte is well-positioned for continued research, development, and potential commercialization of its vaccine candidates. The recent major strategic investment, alongside its substantial total funding, suggests a trajectory towards scaling operations and advancing its pipeline through critical clinical stages. Future developments will likely focus on translating its innovative vaccine platforms into tangible public health solutions, potentially expanding its therapeutic reach and solidifying its market leadership in the vaccine industry. The company's strategic financing rounds indicate a robust plan for growth and innovation.
See full Vaxcyte company page
